1.0700
08-October-24 10:02:23
15 minutes delayed
Stocks
0.0000
0.00%
Today's range
1.0700 - 1.1100
ISIN
N/A
Source
NASDAQ
IO Biotech Announces Publication of Phase 1/2 Melanoma Clinical Trial Results in Nature Medicine
09 Dec 2021 11:05:00 By Nasdaq GlobeNewswire
IO Biotech Announces Third Clinical Collaboration with Merck to Evaluate IO102-IO103 in Combination With KEYTRUDA® (pembrolizumab) as First-Line Treatment in a Phase 2 Multi-Arm Basket Trial
06 Dec 2021 08:00:04 By Nasdaq GlobeNewswire
IO Biotech, Inc. Announces Closing of Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
09 Nov 2021 11:06:22 By Nasdaq GlobeNewswire